The FDA has approved a new drug that not only treats a rare genetic disease that causes extremely high cholesterol levels, but does so using first-of-its-kind technology that has been enhanced ...

Basel, December 22, 2021 — Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio ... to lower low-density lipoprotein cholesterol (also known as bad cholesterol ...

to the U.S. Food and Drug Administration (FDA) seeking approval of Lerodalcibep to reduce low-density lipoprotein cholesterol (LDL-C) for the treatment of patients with atherosclerotic ...

Basel, December 22, 2021 — Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio ® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower ...